Marion Provost

Dechert (Paris)
Lawyer (Senior Associate)

Marion Provost is a senior associate in Dechert’s Paris competition team. Her practice focuses on all areas of competition law work. She is involved in a number of high profile mergers, cartel investigations, and abuse of dominance cases, and regularly advises clients both before the European and French competition authorities and courts. Ms. Provost works for clients in various industries with a particular focus on the life sciences and food sectors, as well as the press sector, financial services and consumer goods. She has taught competition law at several French universities and regularly contributes to writing articles on the latest developments in competition law. Prior to joining Dechert, Marion gained experience at other leading international law firms, including Linklaters and Norton Rose Fulbright.

Linked authors

Dechert (Paris)
Dechert (Paris)
Dechert (Paris)


1169 Bulletin

Marion Provost, Mélanie Thill-Tayara, Simon Hetsch, Sophie Pele The EU General Court annuls a decision of the Commission for wrongly qualifying agreements as "pay for delay" and improperly qualifying an abuse of dominance and so reduces the fine imposed on a pharmaceutical company (Servier)


On 12 December 2018, the General Court (“Court”) partially annulled the European Commission’s decision of 9 July 2014 in the Servier case and consequently reduced Servier’s fine by more than 30%, from €330.99 million to €228.32 million. After the Lundbeck judgment of 8 September 2016, this second (...)

Marion Provost, Mélanie Thill-Tayara Dominance in the pharmaceutical sector: An overview of EU and national case law


The pharmaceutical sector stands out as being regularly on the radar of competition authorities throughout Europe, with no less than 7 decisions adopted within the last 18 months and multiple on-going investigations, covering a wide range of practices, from excessive pricing to pay for delay, refusal to supply and, more generally, commercial strategies implemented by pharmaceutical companies to delay generic or biosimilar entry.

Send a message